Metabolic / appetite
Semaglutide
Mechanism not verified by source image · Peptide
Evidence at a glance
Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.
Open in the interactive library →Compare with other compounds →
Records (1)
H
Human clinical / research
Human clinical / research
Ozempic prescribing information
Administration reported for this specific study or labeled indication.
Context: Patients meeting Ozempic labeling
Approved product label: Amount: 0.25 mg initiation for four weeks, then 0.5 mg; additional increases depend on indication; Route: Subcutaneous; Frequency: Once weekly; Species: Human; Population: Patients meeting Ozempic labeling
Limitations: The source concerns the Ozempic injectable formulation and its approved indications.
Route: Subcutaneous
Open this exact record in the library →Suggest a correction
CONTINUE THE RESEARCH
Follow the pathway.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →
Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.